INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting
Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators presented positive Phase 2 clinical results for EBV-specific T cells in patients with
View HTML
Toggle Summary Atara Biotherapeutics Highlights Next-Generation and Off-the-Shelf, Allogeneic CAR T Technologies and Pipeline
Atara has assembled core technologies and capabilities to develop next-generation and off-the-shelf, allogeneic CAR T immunotherapies, collaborating with academic leaders as well as leveraging the Company’s world-class T cell manufacturing and research expertise with the goal of rapidly advancing
View HTML
Toggle Summary Atara Biotherapeutics to Host CAR T Breakfast Teach-In on November 29, 2018
SOUTH SAN FRANCISCO, Calif. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that the Company will
View HTML
Toggle Summary Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
Findings reported in an article online and to be published in the December 2018 issue of the JCI Insight SOUTH SAN FRANCISCO, Calif. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel
View HTML
Toggle Summary Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress
SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the
View HTML
Toggle Summary Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018
Moffitt Cancer Center collaborators to present next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators to present new tab-cel ®  ( tabelecleucel)  Phase 2 clinical results for patients with
View HTML
Toggle Summary Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported the grant of inducement
View HTML
Toggle Summary Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
SOUTH SAN FRANCISCO, Calif. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Roy Baynes , M.D.,
View HTML
Toggle Summary Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
Focus on multi-targeted CAR T immunotherapies for patients with acute myelogenous leukemia (AML) and B-cell malignancies Collaboration includes novel CAR T targeting and signaling domains designed to optimize T cell proliferation and enhance persistence SOUTH SAN FRANCISCO, Calif. , Sept.
View HTML
Toggle Summary Atara Biotherapeutics to Participate at Two Upcoming Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that members of the
View HTML